Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
LIVMARLI® (maralixibat) oral solution is a minimally absorbed ileal bile acid transporter (IBAT) inhibitor which received FDA approval for treatment of cholestatic pruritus in patients with progressive familial intrahepatic cholestasis.
Lead Product(s): Maralixibat
Therapeutic Area: Genetic Disease Product Name: Livmarli
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2024
Details:
Livmarli (maralixibat) oral solution is an orally administered, once-daily, ileal bile acid transporter (IBAT) inhibitor, which is under phase 2 clinical development for the treatment of Biliary Atresia.
Lead Product(s): Maralixibat
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Livmarli
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
Livmarli (maralixibat) oral solution is an orally administered, once-daily, ileal bile acid transporter (IBAT) inhibitor and NMPA has accepted the New Drug Application for the treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis.
Lead Product(s): Maralixibat
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Livmarli
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2023
Details:
Chenodiol (chenodiol) tablets is a naturally occurring bile acid, which is investigated for the treatment of adult patients with cerebrotendinous xanthomatosis.
Lead Product(s): Chenodeoxycholic Acid
Therapeutic Area: Rare Diseases and Disorders Product Name: Chenodal
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2023
Details:
Under the agreement, Mirum will purchase Travere’s bile acid product portfolio including, Cholbam, indicated for the treatment of bile acid synthesis disorders and Chenodal, indicated for the treatment of radiolucent stones in the gallbladder.
Lead Product(s): Cholic Acid
Therapeutic Area: Genetic Disease Product Name: Cholbam
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Travere Therapeutics
Deal Size: $445.0 million Upfront Cash: $210.0 million
Deal Type: Divestment July 17, 2023
Details:
Livmarli® (maralixibat) oral solution is an orally administered, once-daily, ileal bile acid transporter (IBAT) inhibitor being developed for the treatment of biliary atresia in infant who have previously undergone a hepatoportoenterostomy.
Lead Product(s): Maralixibat
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Livmarli
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2023
Details:
Livmarli® (maralixibat) oral solution is an orally administered, once-daily, ileal bile acid transporter (IBAT) inhibitor approved by the U.S. FDA for the treatment of cholestatic pruritus in patients with alagille syndrome one year of age and older.
Lead Product(s): Maralixibat
Therapeutic Area: Genetic Disease Product Name: Livmarli
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2023
Details:
Livmarli™ (maralixibat) is a reversible inhibitor of the ileal bile acid transporter (IBAT). It decreases the reabsorption of bile acids (primarily the salt forms) from the terminal ileum.
Lead Product(s): Maralixibat
Therapeutic Area: Genetic Disease Product Name: Livmarli
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
Livmarli® (maralixibat) oral solution is an orally administered, once-daily, ileal bile acid transporter (IBAT) inhibitor approved by the U.S. FDA for the treatment of cholestatic pruritus in patients with alagille syndrome one year of age and older.
Lead Product(s): Maralixibat
Therapeutic Area: Genetic Disease Product Name: Livmarli
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2023
Details:
LIVMARLI® (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older, and in Europe for the same indication in patients two months of age and older.
Lead Product(s): Maralixibat
Therapeutic Area: Dermatology Product Name: Livmarli
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2022